Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

Gastroenterology

Volumn 124, Issue 4, 2003, Pages 889-893

  Pardi, Darrell S ^a,b   Loftus Jr , Edward V ^a   Kremers, Walter K ^a   Keach, Jill ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL DYSPLASIA; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

EID: 0037382288     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50156     Document Type: Article

References (35)

1. Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:459-477.
2. Weisner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79:200-206.
3. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-1649.
4. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-1408.
5. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41: 522-525.
6. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, Church JM, Navarro G, Fazio VW. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285-1288.
7. Leidenius MH, Farkkila, MA, Karkkainen P, Taskinen EI. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997;32: 706-711.
8. Brentnall TA, Haggitt RC, Ravbinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-338.
9. Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102: 1877-1880.
10. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88:1174-1178.
11. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastorenterol 1996;91:44-48.
12. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis. Cancer 1998;82:822-826.
13. Gurbuz AK, Giardello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995;38:37-141.
14. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996;110:432-440.
15. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW, Earnest DL. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998;31:111-118.
16. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Can Res 1999;18:259-266.
17. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jap J Cancer Res 1998;89:1009-1013.
18. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Chemoprevention of azomethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994;54:5071-5074.
19. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994;83:319-323.
20. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998;134:129-139.
21. Tung BY, Emond MJ, Haggit RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
22. Lindor KD. The Mayo PSC/UDCA Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-695.
23. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-1294.
24. Rubin PH, Freidman S, Harpaz N, Goldstein E, Weiser J, Schiller J, Waye JD, Present DH. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-1300.
25. Wolf JM, Rybicki L, Lashner BA. Ursodeoxycholic acid is not chemopreventive for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis (abstr). Gastroenterology 2001;120:A447.
26. Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987;2:185-186.
27. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-151.
28. Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988;38:315-320.
29. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977;39:2533-2539.
30. Ochsenkuhn T, Bayerdorffer E, Meining A, Schinkel M, Thiede C, Nussler V, Sackman M, Hatz R, Neubauer A, Paumgartner G. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-1669.
31. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998;58:1684-1687.
32. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-1844.
33. Wali RK, Frawley BP, Hartmann S, Roy HK, Khare S, Scaglione BA, Earnest DL, Sitrin MD, Brasaitus TA, Bissonette M. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of colon carcinogenesis: potential roles of protein kinase C-α, -βII, and -ζ. Cancer Res 1995;55:5257-5264.
34. Roy HK, Bissonnette M, Frawley BP, Wali RK, Niedziela SM, Earnest D, Brasitus TA. Selective preservation of protein kinase C-ζ in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett 1995;336:143-145.
35. Khare S, Wali RR, Cerda SR, Nguyen LT, Hart JA, Stoiber D, Sitrin MD. Ursodeoxycholic acid and a flourinated analogue of 1,25 (OH)2 vitamin D3 inhibit COX-2 overexpression in AOM-induced colonic carcinogenesis. Gastroenterology 2000;188:A682.